WO2003052066A3 - Klcs as modifiers of the p53 pathway and methods of use - Google Patents

Klcs as modifiers of the p53 pathway and methods of use Download PDF

Info

Publication number
WO2003052066A3
WO2003052066A3 PCT/US2002/039633 US0239633W WO03052066A3 WO 2003052066 A3 WO2003052066 A3 WO 2003052066A3 US 0239633 W US0239633 W US 0239633W WO 03052066 A3 WO03052066 A3 WO 03052066A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
klcs
modifiers
klc
Prior art date
Application number
PCT/US2002/039633
Other languages
French (fr)
Other versions
WO2003052066A2 (en
Inventor
Michael A Costa
Tak Hung
Diane Parry
Mark E Maxwell
Mark Lackner
Original Assignee
Exelixis Inc
Michael A Costa
Tak Hung
Diane Parry
Mark E Maxwell
Mark Lackner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Michael A Costa, Tak Hung, Diane Parry, Mark E Maxwell, Mark Lackner filed Critical Exelixis Inc
Priority to AU2002357817A priority Critical patent/AU2002357817A1/en
Publication of WO2003052066A2 publication Critical patent/WO2003052066A2/en
Publication of WO2003052066A3 publication Critical patent/WO2003052066A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

Human KLC genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of KLC are provided.
PCT/US2002/039633 2001-12-13 2002-12-12 Klcs as modifiers of the p53 pathway and methods of use WO2003052066A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002357817A AU2002357817A1 (en) 2001-12-13 2002-12-12 Klcs as modifiers of the p53 pathway and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34032301P 2001-12-13 2001-12-13
US60/340,323 2001-12-13

Publications (2)

Publication Number Publication Date
WO2003052066A2 WO2003052066A2 (en) 2003-06-26
WO2003052066A3 true WO2003052066A3 (en) 2004-01-15

Family

ID=23332856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039633 WO2003052066A2 (en) 2001-12-13 2002-12-12 Klcs as modifiers of the p53 pathway and methods of use

Country Status (2)

Country Link
AU (1) AU2002357817A1 (en)
WO (1) WO2003052066A2 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CABEZA-ARVELAIZ Y. ET AL.: "Cloning and genetic characterization of the human kinesin light-chain (KLC) gene", DNA AND CELL BIOLOGY, vol. 12, no. 10, 1993, pages 881 - 892, XP002965518 *

Also Published As

Publication number Publication date
AU2002357817A8 (en) 2003-06-30
AU2002357817A1 (en) 2003-06-30
WO2003052066A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
WO2002099053A3 (en) Slc22as as modifiers of the p53 pathway and methods of use
WO2002099074A8 (en) Slc7s as modifiers of the p53 pathway and methods of use
WO2003074674A3 (en) MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2003006614A3 (en) UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A8 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099038A3 (en) Adsls as modifiers of the p53 pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2003052066A3 (en) Klcs as modifiers of the p53 pathway and methods of use
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004015069A3 (en) MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE
WO2003033656A3 (en) MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2004024881A3 (en) LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2005003306A3 (en) Sppls as modifiers of the p53 pathway and methods of use
WO2003066811A3 (en) Msrebps as modifiers of the srebp pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP